Brighthouse Financial enters Thursday's session with a Q1 earnings miss freshly on the tape — and options traders had already rotated bullish before the numbers hit.
The results were out after the close on May 6. Adjusted EPS came in at $4.35, missing the $4.66 consensus estimate. Revenue of $1.53 billion missed by a wide margin against the $2.22 billion Street forecast. That double miss will be the focus when the stock opens for trading, and it arrives at a moment when the positioning picture was, until very recently, more optimistic than it has been in months.
The options signal ahead of the print was striking. Call demand surged relative to puts — the put/call ratio collapsed to 0.83 on May 5, nearly four standard deviations below its 20-day average of 1.02. That reading was the most bullish tilt in the PCR all year. Just weeks earlier the ratio was running above 1.10, reflecting defensive hedging. The rapid rotation into calls was a bet that earnings would clear the bar. It did not.
Short interest adds a layer of complexity to the setup. Shorts hold roughly 11.6% of the free float — a meaningful level — and that position has barely moved over the past month, edging up just 2% since early April. Days to cover runs close to ten sessions, per the FINRA fortnightly data. That kind of depth means any sustained selling pressure post-results has a patient, well-sized short base sitting alongside it. The borrow market itself remains relaxed: cost to borrow is around 0.51%, and while that is up 25% over the past month, the absolute level is cheap. Availability has eased sharply from a peak utilization near 11.7% in mid-April to roughly 5.7% now, meaning new shorts face no friction entering the trade.
The Street has spent the past several months moving toward the sidelines on BHF. Barclays downgraded to Equal-Weight in January. Raymond James cut from Strong Buy to Market Perform back in November. The consensus has settled at a cautious Hold across seven analysts, with a mean price target near $65 — modest upside from the $62.73 pre-earnings close. Morgan Stanley has maintained an Underweight throughout, with a target well below the current price. Note that several of the target price inputs are from late 2025 and may not fully reflect the Q1 miss; the consensus figure should be treated as a directional guide rather than a precise anchor until analysts respond to tonight's release. Valuation looks undemanding at a P/E of 3.2x and price-to-book of 0.58x, but cheap multiples in insurance are rarely a catalyst on their own. The 12-month forward EPS growth estimate ranks in the 97th percentile of the universe — a high bar that a below-consensus print makes harder to defend.
Institutional ownership offers one potentially stabilising factor. Vanguard and BlackRock together hold close to 19% of shares, and BlackRock added over 100,000 shares in April. American Century also added 136,000 shares that month. Greenlight Capital and Glazer Capital — both known as active, thesis-driven managers — are among the top holders, which suggests at least part of the register has conviction rather than passive exposure.
Q4 2025 results in February produced a 3.2% one-day decline and a 6.3% five-day drop, the most negative reaction in recent quarters. That prior-print pattern, combined with tonight's miss on both lines, sets the frame for what to watch Thursday: how quickly the PCR rotates back toward puts, whether short interest ticks higher in the days following, and whether any of the Hold-rated analysts use the miss as a prompt to revisit their targets.
See the live data behind this article on ORTEX.
Open BHF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
